Adolescent and young adult (AYA) oncology patients experience many physical and psychological symptoms at the end of life (EOL); however, data on these experiences for AYA patients who have undergone hematopoietic cell transplantation (HCT) remains sparse. We sought to investigate the characteristics of AYA patients aged 15 − 25 years who received allogeneic HCT and subsequently died while inpatient at our institution between the years 2008 and 2014. A standardized data extraction tool was used to collect information about patient demographics, treatment and symptoms. We found that during this time frame, 34 AYA patients had received HCT and died while inpatient at our institution, 23 (68%) of whom died because of treatment-related complications. Compared with non-HCT AYA oncology patients (n = 35), patients who received HCT (n = 34) were more likely to have died in the intensive care unit (71% vs 23%, P o 0 .0001) and to have received mechanical ventilation (68% vs 17%, Po 0.0001) or hemodialysis (53% vs 0%, P o0.0001) in the last 30 days of life. These findings demonstrate that AYA patients who receive allogeneic HCT receive intensive EOL treatment, suggesting that these patients may benefit from early integration of expert interdisciplinary services to prospectively assess and manage distressing symptoms.
INTRODUCTION
Adolescent and young adult (AYA) patients, defined by the National Cancer Institute as patients between the age of 15 and 39 years, 1 represent a unique population with distinct epidemiological, genetic and psychosocial characteristics. Cancer remains one of the leading causes of nonaccidental death for patients in this age range, 2, 3 and improvements in cancer treatment and survival that have been noted in younger pediatric or older adult patients have not yet been realized in this cohort. 2, [4] [5] [6] In addition, AYA oncology patients often receive intensive medical services at the end of life (EOL). [7] [8] [9] Compared with younger children, AYA oncology patients have higher rates of hospitalization, more frequent intensive care unit (ICU) admissions and receive more chemotherapy treatments during the last 30 days of life. 8, 9 Likely due, in part, to the intensity of treatment received at the EOL, AYA oncology patients also experience a myriad of physical and psychological symptoms, and many of these symptoms are poorly recognized, understood and treated. [10] [11] [12] [13] Control of symptoms in pediatric and AYA patients at the EOL is important as parental perceptions of suffering are associated with distress 14 and may complicate parental bereavement. 15, 16 In addition, given the age and developmental stage of AYA patients, intensive treatment and poorly controlled symptoms at the EOL may negatively impact grief of those outside the immediate family unit, including peers and partners.
Patients with high-risk or relapsed hematologic malignancies, and certain genetic diseases, may be offered hematopoietic cell transplantation (HCT) as a curative treatment option. 17 Despite significant advances in transplant techniques, including progress in supportive care and greater emphasis placed on symptom management and quality of life, HCT remains a high-risk and intensive therapy with an increased burden of suffering and risk of mortality. [18] [19] [20] [21] Recent studies, using parent report after patient death, have shown that pediatric patients who undergo HCT are more likely to 'suffer highly' from their last therapy and die in the ICU, with less opportunity for EOL care planning. 20, 21 In addition, pediatric oncology patients who underwent HCT had a shorter time interval between completion of a do-not-resuscitate order and death, were enrolled less often in hospice and were less likely to die at home as compared with pediatric oncology patients who did not undergo HCT as a part of their treatment. 22 Based on the authors' collective clinical experience caring for hospitalized AYA oncology patients at the EOL, we hypothesized that this population often receives intensive medical treatments, requires extensive medical and psychosocial resources and experiences significant symptoms and distress at the EOL. We therefore conducted a retrospective study to further investigate this vulnerable and understudied population. Almost half of the patients included in this study had received allogeneic HCT and thus warranted additional examination. To further characterize the end-of-life experiences of AYA patients who receive allogeneic HCT as part of their treatment regimen, we conducted a descriptive retrospective study of the psychosocial, demographic, treatment and EOL characteristics of those patients who died while hospitalized at our institution, a large academic pediatric cancer center. We focused on identifying physical and psychological symptoms documented during the last month of life. We also investigated and compared the differences between EOL characteristics and symptoms of AYA patients who died in the inpatient setting at our institution during this same time period, based on whether or not they had received HCT as a part of their therapy. In addition, we explored differences in EOL features of AYA HCT patients based on their cause of death, regardless of location of death. This descriptive study builds upon very limited literature characterizing the demographic and EOL characteristics of AYA patients who have undergone allogeneic HCT, 20, 22 and to our knowledge it is the first study to assess the physical and psychological symptoms of this uniquely vulnerable patient population during the last month of life. Days from last hospital admission to death Median (IQR) (range) 39 (13-75) (1-168) POST/DNR order in place, n (%) 28 (82%) Received CPR before death, n (%) 7 (21%)
Abbreviations: ANC = absolute neutrophil count; CPR = cardiopulmonary resuscitation; DNR = do not resuscitate; HCT = hematopoietic cell transplant; ICU = intensive care unit; IQR = interquartile range; MDS = myelodysplastic syndrome; POST = physician scope of treatment.
a ANC engraftment was defined as ANC of at least 500/mm 3 for 3 consecutive days. Platelet engraftment was defined as the first day on which the platelet count was at least 20 × 10 3 /mm 3 , without transfusion in the preceding 7 days.
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MATERIALS AND METHODS
Study design
This study was conducted at St Jude Children's Research Hospital (St Jude). The hospital's institutional review board deemed the study to be exempt in the setting of a retrospective analysis of a deceased cohort. A list of all patients aged ⩾ 15 years who died between 2008 and 2014 was obtained, along with data about each patient's age at death, date of death and primary medical service. Demographic data and information related to each patient's treatment and EOL experiences were collected by chart review. A data abstraction tool (Supplementary Material) was created based on a literature review 10, 11, [23] [24] [25] in consultation with oncology and palliative care (PC) experts. Two researchers (JMS and JL) worked together to collect data on a standardized form for the first 20 patients. Thereafter, JL conducted primary data abstraction; data for every third patient was independently collected by both researchers. Concurrent review of the medical record with real-time discussion was used to reach consensus for any discrepancies in data recording. In addition, for any questions regarding medical records for patients reviewed by a single researcher, the second reviewer independently reviewed the entire record for that patient to answer questions and the two reviewers subsequently met and reviewed the charts together until consensus was reached. No categories of the medical record or data tool demonstrated ongoing difficulty with discrepant results. All medical record components from 30 days before the date of death were reviewed including inpatient and outpatient documentation. Other select portions of the medical record were reviewed to obtain information regarding diagnosis, treatment-related sequelae, disease trajectory and EOL experiences. For patients who died before mid-2012, data were obtained from both electronic medical records and hardcopy charts, as documentation was not fully electronic during that time period. Additional details related to the HCT were obtained from an institutional HCT clinical database. Invasive medical procedures were defined as any potentially painful procedure that required analgesia or anesthesia (for example, central or arterial line placement, central line removal, chest tube placement, lumbar puncture or bone marrow aspirate or biopsy).
Symptom burden was assessed using the data abstraction tool described above. The domains captured by this tool have been previously described. 7 Each symptom was characterized as present (yes/no) if it was recorded at some point during the last month of life (30 days before death), the last week of life (7 days before death) or last day of life (24 h before death). We chose not to present the duration of each symptom during the last month of life, given variation in potential documentation of symptoms based on location of care during the last month of life.
Statistical analysis
Demographic, treatment and EOL characteristics of patients were summarized using descriptive statistics. The χ 2 and Fisher's exact tests were used to examine differences for categorical variables between patient subgroups. Wilcoxon rank sum tests were used to examine differences for continuous variables between patient subgroups. Patient subgroups were defined by receipt of an allogeneic HCT as part of treatment (yes/no) and cause of death (progressive disease or secondary malignancy vs treatment complications). Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). A two-sided significance level of P o0.05 was used for all statistical tests. Raw P-values are reported, but were adjusted for multiple testing using the false discovery rate adjustment to determine statistical significance. Table 1 . The EOL characteristics of this cohort have been previously described. 7 Demographic and clinical characteristics of the 34 AYA patients who received allogeneic HCT and subsequently died while inpatient at St Jude are summarized in Table 2 . Of the 7 patients (21%) who received cardiopulmonary resuscitation during their final admission, none had a do-not-resuscitate order in place at the time of resuscitation. Only two patients survived an initial resuscitation attempt, and both subsequently had a do-notresuscitate order placed; one patient died later that same day and the second died 18 days following the initial resuscitation. Of the 11 patients who received HCT and subsequently died of progressive disease, 2 (18%) received cardiopulmonary resuscitation during their final hospital admission. Table 3 summarizes the treatment characteristics of the 34 AYA patients who received allogeneic HCT as part of their treatment and died while inpatient at St Jude. During the last month of life, these patients received intensive medical care, with 23 (68%) receiving mechanical ventilation, 32 (94%) receiving supplemental oxygen, 18 (53%) receiving dialysis and 28 (82%) undergoing at least one invasive medical procedure. Symptom characteristics at EOL AYA patients who received allogeneic HCT and died inpatient at St Jude (n = 34) had a median of 11.5 (interquartile range, [10] [11] [12] [13] [14] documented symptoms during the last month of life, with 27 (79%) patients having at least 1 documented refractory symptom. Figure 1 summarizes the symptoms present during the last month, week and day of life for this patient cohort, dichotomized as yes/ no at any point during the last 30 days of life, the last 7 days or life or the last day of life. The most common symptoms in the last month of life were pain (97%), fatigue (91%) and edema/ lymphedema (82%).
RESULTS
Demographic and clinical characteristics
Treatment characteristics at EOL
Comparison of characteristics by receipt of transplant
Characteristics of AYA patients who did (n = 34) or did not (n = 35) receive allogeneic HCT as part of their treatment regimen, and subsequently died while inpatient at St Jude, are summarized in Table 4 . Involvement of the PC team in the last 30 days of life was similar between both patient cohorts (P = 0.377). Compared with non-HCT AYA oncology patients, those who had received HCT were more likely to die in the ICU (P o0.0001), to receive hemodialysis in the last month of life (P o0.0001) and last day of life (P o0.001) and to be mechanically ventilated during both the last month of life (P o0.0001) and the last day of life (P o0.001).
Patients who underwent HCT experienced a greater number of medical procedures in the last 30 days of life (P o 0.001); however, they were less likely to receive chemotherapy during this time period (P = 0.001). The number of both physical and psychosocial symptoms in the last month of life was comparable between the AYA patient cohorts. Compared with those who did not receive HCT, AYA HCT patients were more likely to have diarrhea (26% vs 74%, P o 0.0001) and were less likely to have constipation (66% vs 15%, P o 0.0001). Table 5 . Forty-two (79%) patients died in the hospital, 34 at our institution and 8 at another hospital. Only 8 patients (15%) died at home and the location of death was not found for 3 patients. AYA HCT patients who died of treatment complications (n = 24) were more likely to die in the hospital compared with those who died of either progressive disease or second malignancy (n = 29) (P = 0.004). Compared with AYA HCT patients who died of treatment-related complications, patients who died of progressive disease or second malignancy had a significantly longer period of time from their last HCT to death (P o 0.001).
Comparison of characteristics and symptoms by cause of death
DISCUSSION
AYA patients who underwent allogeneic HCT as part of their treatment regimen received intensive medical treatment at the EOL, as evidenced by the large percentage of patients who received mechanical ventilation, hemodialysis and invasive medical procedures during the last month of life. This patient cohort also received extensive interdisciplinary and psychosocial supportive services (for example, pain service, psychology and PC) during their EOL period. Of the AYA patients who received allogeneic HCT, 79% died in the hospital; these data are consistent with literature suggesting that children who receive HCT are more likely to die in a medical setting when compared with pediatric oncology patients who do not receive HCT.
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Of the 34 AYA HCT patients who died while hospitalized at St Jude, 71% died in the ICU. In addition, 35% of the patients in this cohort died of treatment-related complications that may be associated with increased use of intensive life-prolonging and intensive medical interventions, likely related to prognostic uncertainty. 26 These findings are important because pediatric patient death in the ICU is associated with a high level of complicated grief symptoms in parents 6 months after their child's death 27 and severe complicated grief persists up to 18 months following death. Figure 1 . Symptoms present during the last month, last week, and last day of life for adolescent and young adult patients who received allogeneic hematopoietic cell transplant and died while inpatient at St Jude (n = 34).
AYA patients who received allogeneic HCT as part of their treatment regimen experienced significant symptom burden during the last month of life, likely as a result of the intensive treatments received. Proper assessment and management of symptoms is essential in AYA patients who undergo HCT throughout their treatment course, but is especially important at the end of life. These findings highlight the importance of an integrative interdisciplinary team approach to address and treat symptoms in this high-risk population. An integrated PC and HCT framework can be used to conduct frequent, prospective, patientreported symptom and distress assessments in patients undergoing HCT. This information could be applied clinically to address and treat distressing or persistent symptoms, with interdisciplinary team members brought in to augment treatment of refractory symptoms. Management may include a variety of modalities in combination with pharmacotherapy, including psychological support, integrative methods and interventional or regional anesthetic approaches. Symptom and distress assessments could be used in a research context to provide baseline data with which to study the effect of interventions on improving the care and quality of life of patients and their families during therapy, and at the EOL. We hypothesize that early integration of PC clinicians with expertise in assessing and managing distressing symptoms may help to alleviate patient and family suffering secondary to persistent or refractory symptoms. Recent data from adult patients undergoing HCT for the treatment of hematologic malignancies demonstrate that integration of PC mitigates transplant-related reduction in patient quality of life as early as 2 weeks after transplant, although long-term impact on quality of life remains less well demonstrated. 29 Although the general principles of PC for both pediatric and adult patients are readily transferrable to AYA HCT patients, there are distinct psychosocial, ethical, developmental, spiritual and existential issues that characterize this group of patients. AYA patients with cancer may be uniquely positioned to benefit from integration of PC with routine oncology and HCT care that includes appropriate assessment and management of refractory or persistent symptoms, developmentally appropriate psychological and integrative approaches to symptom management and inclusion of AYA patients in medical decision-making processes. Effective PC requires creation of an individualized care plan, 24 and we advocate for integration of this plan into the care of high-risk AYA patients early in their disease course, allowing for PC principles to guide conversations and decision making before HCT, during the post-HCT period, and at times of relapse or disease progression. [30] [31] [32] Although the majority of patients included in this study received PC support during their last month of life, we believe that all patients who undergo allogeneic HCT should have access to expert consultation in symptom management and advanced care planning given evidence of high symptom burden and risk of further disease progression, relapse or treatment-related complications. In the context of these study findings, our institution has invested in a system to integrate PC into the routine care of AYA Table 4 . End-of-life characteristics of adolescent and young adult patients who died while inpatient at St Jude by receipt of allogeneic hematopoietic stem cell transplant HCT patients. This model of PC integration is designed to provide varying levels of support for patients and families, based on clinical status and patient and family need, originating before transplant and extended into the EOL period and into bereavement. Prospective evaluation of the effectiveness of this model is ongoing and includes patient-reported symptoms that we hope will build upon the early foundation established by this study's results.
Our study has several limitations. Given the retrospective nature of chart review, the data represent only that information documented in the medical record. To address concerns regarding the potential for incomplete information, we maximized the data collection process by dual abstraction from both electronic and paper records. Data on the EOL characteristics of patients were more completely documented for patients who died while hospitalized but were limited or not present for patients who died elsewhere. In addition, no standardized assessment tool to identify and document patient symptoms was used at our institution during the time frame of this study; therefore, the medical record primarily reflects what clinicians observed or obtained from patient or parental reports. In the era of patientreported outcomes and prospective symptom assessment, this is a major limitation. However, the literature describing prospectively collected data on the symptoms experienced by pediatric oncology patients at the end of life is extremely limited and does not include patients who underwent HCT. 33 In the absence of any prospective symptom data for AYA patients who undergo HCT, these retrospective data provide a meaningful step toward filling this knowledge gap. We obtained the number of symptoms at the end of life, but not severity and associated level of distress. The data on the presence of documented symptoms during the last month, last week and last day of life may also be affected by whether or not the patient was hospitalized during that time frame and the number of days that a patient was hospitalized. However, even patients who were not hospitalized during the last 30 days of life had regular documentation via outpatient or homebased visits (typically 3-5 times per week). By conducting this study within a tertiary institution that offers experimental and Table 5 . Characteristics of deceased adolescent and young adult patients who received allogeneic hematopoietic cell transplant by cause of death
Characteristics
Cause of death P Progressive disease or second malignancy (n = 29) Treatment complications (n = 24)
early phase trials, there may be selection bias toward patients with relapsed or refractory oncologic diseases who wish to pursue aggressive and/or experimental therapy. Despite these limitations, we believe our findings provide meaningful insights into the characteristics, illness and EOL experiences of AYA patients who undergo HCT and die while hospitalized. In summary, AYA patients who undergo allogeneic HCT and die in the hospital receive intensive therapy and require significant medical care and support at the EOL. As a result, these patients experience a large number of symptoms during their last month of life. Early integration of PC into the care of patients undergoing allogeneic HCT may result in improved symptom management and may lead to fewer intensive interventions at the EOL. Further prospective investigation is needed to determine the effect of early PC integrative services on the illness and EOL experiences of AYA HCT patients and their families.
